Month: May 2023

VANCOUVER, British Columbia, May 26, 2023 (GLOBE NEWSWIRE) — DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB US: DMGGF) (FRANKFURT: 6AX) (“DMG” or the “Company”), a vertically integrated blockchain and cryptocurrency technology company, today announces it will release financial results for its second quarter 2023 ending March 31, 2023 on Tuesday, May 30 after the market close. The Company will host a conference call to review its results and provide a corporate update on May 31, 2023 at 4:15 pm ET. DMG Receives Energy Web’s Certification for Sustainable Bitcoin Mining DMG announces it is among the first five miners to be certified for sustainable Bitcoin mining by Energy Web, which is an independent non-profit that develops open-source software for clean energy solutions. On May 24, Energy Web announced its launch of Green Proofs...

Bagsværd, Denmark, 26 May 2023 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending once-weekly Sogroya® (somapacitan) for replacement of endogenous growth hormone (GH) in children aged three years and above, and adolescents with growth failure due to growth hormone deficiency. Symptoms of growth hormone deficiency in children often start early in life, leading to short stature as well as other growth-related health problems.1 Current treatment for growth hormone deficiency typically requires daily injections of growth hormone.2 However, frequent injections can be burdensome, disrupting daily life, reducing adherence and thereby affecting clinical outcomes – particularly in children.3 “Today’s positive CHMP opinion is...

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM AN OFFER FOR SALE OF, OR THE SOLICITATION OF AN OFFER TO BUY, THE SECURITIES REFERRED TO HEREIN IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW.Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 MillionTo access the press release, please click here.

Basel, 26 May 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held 2 – 6 June.  Highlights include new data spanning treatments for lymphoma and hepatocellular carcinoma (HCC): Developing new treatment options for people with blood cancersExtended follow-up data for Columvi® (glofitamab) of almost two years (20 months) from the pivotal phase II NP30179 study, further investigating the potential of fixed-duration Columvi to provide durable responses in people with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) Early data from the phase Ib NP40126 study of Columvi in combination with Polivy plus rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP)...

Regulated Information Nyrstar NV releases notice for the 2022 annual general shareholders’ meeting to be held on 27 June 2023 26 May 2023 at 07.00 CEST Nyrstar NV (the “Company”) today issued the notice for the 2022 annual general shareholders’ meeting to be held on 27 June 2023 at 10:00 a.m. CEST. The annual general meeting will be held physically with no virtual option available. The practical modalities of the meeting are set out in the notice to the meeting which has been published on the Company’s website (https://www.nyrstar.be/en/investors/share-and-bondholder-information/shareholder-meetings). The full notice, including agenda, proposed resolutions and explanatory note can be found on the aforementioned Nyrstar NV website. About Nyrstar NV The Company is incorporated in Belgium and is listed on Euronext Brussels under the...

   CNOVA N.V. – Opening of conciliation proceedings at Cdiscount Amsterdam – May 26, 2023, 7:00 CET – Cnova N.V. (Euronext Paris: CNV; ISIN: NL0010949392) (“Cnova” or the “Company”) and its Board of Directors announce the opening of conciliation proceedings at Cdiscount level. On May 23, 2023, the French Company’s subsidiaries: Cdiscount, Maas, C-Shield, C-Technology, C-Logistics, Carya and CLR, requested from the President of the Paris Commercial Court the opening of conciliation proceedings to their benefit, under the aegis of SELARL BCM (Me Eric Bauland) and of SCP BTSG² (Me Marc Sénéchal), for an initial period of four months, possibly extendable for one additional month. These conciliation proceedings are part of the more global context of the conciliation proceedings opened to the benefit of Groupe Casino, for the purpose of engaging...

WALTHAM, Mass., May 26, 2023 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 22,989,474 shares of its voting common stock at a public offering price of $2.00 per share, and pre-funded warrants to purchase up to an aggregate of 47,010,526 shares of its common stock at a price to the public of $1.9999 per pre-funded warrant, which represents the per share public offering price for the voting common stock less the $0.0001 per share exercise price for each such pre-funded warrant. In addition, TScan has granted the underwriters a 30-day option to purchase up to an additional 10,500,000...

Refinances a meaningful portion of our debt due in June 2024, extending maturity to 2027 and locking in lower fixed interest rate of 5.20%; Strengthens balance sheet with additional cash proceeds of $15 million or $37 million if over-allotment is exercised in full, to be used for strategic acquisitions and to pay down debt; Brings the Company’s current cash, cash equivalents and marketable securities on hand to approximately $440 million. LEAMINGTON, Ontario and NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today announced the pricing of its registered offering of $150 million aggregate principal amount of 5.20% Convertible Senior Notes due 2027 (the “Notes”). Tilray also granted a 30-day...